Clinical Trials

07 Aug 2020
- Clinical Trials
- Human Trials
Daiichi Sankyo, AstraZeneca collaborate to evaluate patritumab deruxtecan in combination with TAGRISSO in EGFR-mutated NSCLC

By PBR Staff Writer

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that it has entered into a clinical trial collaboration with AstraZeneca (LSE/STO/NYSE: AZN) to evaluate the combination of patritumab deruxtecan (U3-1402), a HER3 directed DXd antibody drug conjugate (ADC), and TAGRISSO (osimertinib), an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), in patients with EGFR-mutated advanced or metastatic non-small cell lung cancer (NSCLC).
06 Aug 2020
Clinical Trials
Human Trials
LORBRENA significantly improves progression-free survival in first-line ALK-positive lung cancer

By PBR Staff Writer

Pfizer announced that the Phase 3 CROWN study of LORBRENA (lorlatinib) in people with previously untreated advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) met its primary endpoint by demonstrating significantly improved progression-free survival (PFS), as compared to XALKORI (crizotinib).
05 Aug 2020
Clinical Trials
Human Trials
RLF-100 shown to deliver rapid recovery from respiratory failure in Covid-19 patients

By PBR Staff Writer

NeuroRx and Relief Therapeutics said that RLF-100 (aviptadil) delivered quick recovery from respiratory failure in the most critically ill patients suffering from Covid-19 in a phase 2/3 clinical trial.
04 Aug 2020
Clinical Trials
Human Trials
AbCellera provides Covid-19 programme update with start of phase 3 clinical trials

By PBR Staff Writer

AbCellera announced that LY-CoV555, a human antibody discovered by AbCellera in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC) and co-developed with Eli Lilly and Company (Lilly) as a potential treatment and prophylaxis for Covi-19, has progressed to Phase 3 clinical trials. A first-of-its-kind, the Lilly-sponsored trial will use customized mobile research units to conduct the study at long-term care facilities across the United States.
31 Jul 2020
Clinical Trials
Human Trials
SAB Biotherapeutics announces first participant dosed in phase 1 clinical trial of SAB-176 for seasonal influenza

By PBR Staff Writer

SAB Biotherapeutics (SAB), a clinical stage biopharmaceutical company developing a novel immunotherapy platform to produce fully human polyclonal antibodies without the need for human donors, announced that the first participant has been dosed in its Phase 1 clinical trial evaluating SAB-176 for the treatment of seasonal influenza.
30 Jul 2020
Clinical Trials
Human Trials
Roche’s tocilizumab fails to achieve primary endpoints for Covid-19-related pneumonia

By PBR Staff Writer

Roche’s Actemra/RoActemra (tocilizumab) has failed to achieve the primary endpoint in the phase III trial, which included hospitalised patients with severe Covid-19 associated pneumonia.
29 Jul 2020
Clinical Trials
Human Trials
AstraZeneca’s Farxiga succeeds in phase 3 trial in chronic kidney disease

By PBR Staff Writer

AstraZeneca said that Farxiga (dapagliflozin) has succeeded in a phase 3 trial in chronic kidney disease (CKD) by meeting all its primary and secondary endpoints.
28 Jul 2020
Clinical Trials
Human Trials
AI Therapeutics announces start of phase II trial of LAM-002A to treat Covid-19 patients

By PBR Staff Writer

AI Therapeutics announced the start of Phase II clinical trial for the treatment of newly diagnosed Covid-19 patients in collaboration with Yale University.
28 Jul 2020
Clinical Trials
Human Trials
NeoImmuneTech gets IND clearance for NT-I7 trial in locally recurrent SCCHN

By PBR Staff Writer

NeoImmuneTech announced receipt of IND clearance from the US Federal Drug Administration (FDA) to evaluate NT-I7 (efineptakin alfa), the only clinical-stage long-acting human IL-7, in a Window-of-Opportunity trial for patients with locally recurrent squamous cell carcinoma of head and neck (SCCHN) undergoing salvage surgery.
28 Jul 2020
Clinical Trials
Human Trials
Pfizer, BioNTech begin phase 2/3 Covid-19 trial with BNT162b2 vaccine candidate

By PBR Staff Writer

Pfizer, along with BioNTech, has commenced the phase 2/3 safety and efficacy clinical study to assess a single nucleoside-modified messenger RNA (modRNA) candidate from their BNT162 mRNA-based vaccine programme against SARS-CoV-2.

Drug Discovery

Research & Development

Seismic Bio partners with Twist Bioscience for discovery and optimisation of antibodies

Pfizer says Covid-19 vaccine may be needed regularly

Clinical Trials

Patient Enrollment

Ridgeback begins enrolment for phase 2 Covid-19 trial of EIDD-2801

Theravance Biopharma doses first patient in phase 2 Covid-19 trial with JAKi inhibitor TD-0903

Regulation

Drug Filing

FDA approves IND for PSC’s stem cell therapy candidate for Covid-19

TAGRISSO granted FDA breakthrough therapy status in EGFR-mutated lung cancer

Production & Sales

Manufacturing

J&J announces agreement with US govt for 100 million doses of investigational Covid-19 vaccine

Sanofi, GSK to supply US govt with 100 million doses of Covid-19 vaccine

Packaging & Supply Chain

Packaging

Gerresheimer

PCI Pharma announces bottling line expansion at Rockford site

Suppliers

No data found

Clinical Trials

Daiichi Sankyo, AstraZeneca collaborate to evaluate patritumab deruxtecan in combination with TAGRISSO in EGFR-mutated NSCLC

LORBRENA significantly improves progression-free survival in first-line ALK-positive lung cancer

RLF-100 shown to deliver rapid recovery from respiratory failure in Covid-19 patients

AbCellera provides Covid-19 programme update with start of phase 3 clinical trials

SAB Biotherapeutics announces first participant dosed in phase 1 clinical trial of SAB-176 for seasonal influenza

Roche’s tocilizumab fails to achieve primary endpoints for Covid-19-related pneumonia

AstraZeneca’s Farxiga succeeds in phase 3 trial in chronic kidney disease

AI Therapeutics announces start of phase II trial of LAM-002A to treat Covid-19 patients

NeoImmuneTech gets IND clearance for NT-I7 trial in locally recurrent SCCHN

Pfizer, BioNTech begin phase 2/3 Covid-19 trial with BNT162b2 vaccine candidate

Pharmaceutical Business review is using cookies

Research & Development

Patient Enrollment

Drug Filing

Manufacturing

Packaging

No data found